GLP-1 weight-loss drug boom pushes employers to rethink coverage
TL;DR
Rising use of GLP-1 weight‑loss drugs is driving higher employer healthcare costs, with about two‑thirds of U.S. companies currently covering GLP-1s for weight loss but around 10% planning to drop coverage next year; PepsiCo, Cigna and Starbucks have already limited or ended coverage, while Bank of America’s Moynihan says GLP-1 spending is large yet beneficial for employees, highlighting a broader debate on affordability and value as plans seek sustainability.
Topics:businesshealth#corporate-benefits#employer-coverage#glp-1-drugs#health#healthcare-costs#weight-loss-medications
- America’s enthusiasm for weight-loss drugs is forcing employers to drop coverage Yahoo Finance
- Will Wegovy Be A Part D, A Medicare GLP-1 Bridge Drug Or Neither? Forbes
- Why your healthcare cost strategy is failing - and what to do hcamag.com
- Easing Prior Authorization for GLP-1s aafp.org
- How Weight-Loss Drugs Are Changing Coverage Rules for the Life Insurance Industry Muddy River News
Want the full story? Read the original reporting
Read on Yahoo Finance